<DOC>
	<DOCNO>NCT02252367</DOCNO>
	<brief_summary>At present time several preclinical clinical study demonstrate safety efficacy PDE5 ( phosphodiesterase type 5 ) -inhibitors LUTS/BPH ( low urinary tract symptoms/benign prostatic hyperplasia ) patient without erectile dysfunction . However , link clinical outcome ( symptoms score ) , functional activity ( urodynamic finding ) molecular pathway , particular regard inflammatory pattern ( molecular analysis ) , previously investigate . Aim present study ass , first time literature , change pressure flow study ( PFS ) change molecular profile prostatic tissue ( inflammatory tissue remodel marker ) men treat 12 week tadalafil 5 mg compare placebo correlate data change symptom score ( IPSS , International Prostatic Symptoms Score ) men LUTS secondary BPH refractory alpha blocker .</brief_summary>
	<brief_title>Effect 12 Weeks Treatment With Tadalafil v Placebo Lower Urinary Tract Symptoms Secondary Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>adult male subject plan undergo simple prostatectomy ( TURP , Transurethral resection prostate , open prostatectomy ) benign prostatic hyperplasia ; treatment alphablockers ( Tamsulosin 0.4 mg/die ) capable give informed consent . participation another clinical study ; know suspect presence prostatic cancer PSA ( prostate specific antigen ) value &gt; 10 ng/mL ; suspect lack participant 's compliance ; know severe allergy hypersensitivity study drug ( active substance excipients formulation ) ; nown neurogenic bladder ( i.e . Parkinson 's disease ) ; suspect proven urinary infection ; presence bladder stone .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Phosphodiesterase 5 Inhibitors</keyword>
	<keyword>BPH/LUTS</keyword>
</DOC>